

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

## INDEX

- A**  
 access to technology by women in  
   agriculture 61–2
- Africa**  
   IP protection in 111–12  
   model law 112–15  
   plant biotechnology, usage of  
     109–10  
   plant breeding in 111–12  
   model law protection for 112–15  
   TRIPS, ratification of 115  
   UPOV, adoption of 115
- African Model Legislation as to IP**  
   rights 112–15
- Agreement on Technical Barriers to Trade**  
   (TBT Agreement) 169–70  
   human rights, interaction with 35–6  
   international standards, on use of  
     234–5, 240  
   like products rules, exceptions to  
     266–7
- Agreement on the Application of Sanitary**  
   **and Phytosanitary Measures**  
   (SPS Agreement) 167–9
- Cartagena Protocol, interaction  
     with 171
- human rights, interaction with 35  
     principle of consistency 50
- international standards, use of  
     232–3, 237–8
- like products rules, exceptions to  
     266–7
- precautionary principle, as to 255–6  
     GMOs 232–6, 240–2, 281
- Agreement on Trade-Related Investment**  
   **Measures (TRIPS)** 110–11
- Africa, ratification in 115
- CBD, harmonisation with 114
- health, protection of 85–6, 108
- human rights, as to 38–47, 82, 107
- patents, as to 78  
     animals 78–81, 106  
     ethical considerations 81, 107  
     GMOs 78–81  
     human body and genetic material,  
       as to 81, 106–7  
     plants 78–81, 106
- traditional knowledge, protection of  
     82–5, 107–8, 132–4  
     proposals for strengthening 134–47
- UNESCO Declarations, interaction  
     with 334–41
- agriculture**  
   biodiversity, protection of 189–90
- coexistence of farming methods *see*  
     coexistence in agriculture
- women's issues 59–60, 64  
     access to technology 61–2
- animals, patentability of**  
   Biotechnology Directive 89–91,  
     101, 106
- genes and gene sequences 91
- TRIPS as to 78–81, 106
- anti-trust rules**  
   future trade regulation, influence  
     on 52
- IP regulation, as to 201–2
- attitudes to biotechnology** 18–19
- B**  
   Beijing Declaration, as to gender  
     mainstreaming 67–71
- bio-based industrial products,  
     definition of 152

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

344

INDEX

- biodiesel *see* biofuels
- biodiversity *see also* Convention on Biological Diversity (CBD)
  - agricultural policies to protect 189–90
- biofuels
  - biodiesel
    - production of EC 158
  - biodiesel production
    - Brazil 156
    - USA 156–7
  - developing countries, production in 158
  - EC production of 157–8
  - environmental benefits of 155–6
  - environmental impacts of 165–6
  - ethanol
    - production of 156
      - biorefineries 162
      - Brazil 156
      - corn, use of 156–7, 160–1
      - EC 158
      - tax credit system (USA) 157
  - first and second generation fuels compared 159
  - plant sources of 155
  - production of
    - costs and competitiveness 161–2
    - techniques 159–61
  - R&D 162–4
  - trading
    - benefits from 164–5
    - risks 165–6
  - WTO measures relating to 166–73
- biogas production process 155
- biological resources
  - African Model Legislation as to 112–15
  - Biotechnology Directive as to 88–9
  - sharing benefits from use of 10
  - traditional knowledge, relationship to 120–1
- biomass, definition of 155
- biopiracy 121–2
- bioprospecting 121–2
- biorefineries 162
- Biosafety Protocol *see* Cartagena Protocol on Biosafety (Cartagena protocol)
- Biotech case (EC-Biotech)* 168
  - interpretation of WTO agreements, on 171–3
- biotechnology companies and research bodies, worldwide distribution 163
- Biotechnology Directive (EC)
  - biological material, as to 88–9
  - ethical concerns, as to 94–6, 102–3, 107
  - European Patent, impact on 88
  - health and healthcare issues 105–6
  - human body and genetic material, as to 91–4, 101–2, 106–7
  - human rights, as to 96–8, 103, 107
  - implementation by EC member states 100–6
  - patenting of animals 89–91, 101, 106
  - recombinant proteins, as to 88–9
  - traditional knowledge, protection of 98–100, 103–4, 107–8
- biotechnology industry, development by developing countries 12
- Brazil
  - biodiesel, use of 156
  - ethanol production 156
- burden of proof, human rights issues 49
- C
- carbon dioxide emissions *see under* energy sector
- Cartagena Protocol on Biosafety (Cartagena protocol) 166–7, 234–5, 240
  - categories of LMOs 208–9
  - definition of LMOs 166, 175
  - environmental and trade measure, as mixed 209–10
  - precautionary principle, as to 167, 234–5, 240, 255–6
  - risk assessment 209, 233–4, 238–40
  - role of 196–8, 208
  - SPS Agreement, interaction with 171
  - trade restriction, as instrument of 211–12
  - WTO Agreements, interaction with 7, 8, 11, 170–1, 198–200, 210–11, 215

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

- absence of hierarchy 227
- Biotech case as to 171–3
- dispute settlement 235, 237–40, 242–4
- no hierarchy, mutual
  - supportiveness and
  - deference principle 276–7
- case law
  - conflicts between Agreements, as to 220–1
  - human dignity considerations in regulating cross-border gambling, as to 298–300
  - precautionary principle, as to 232–6, 240–2
- cloning *see* human cloning
- Codex Alimentarius* standards
  - risk assessment, for 235–6, 244–5
  - use in international trade agreements 232–6, 240–2
- coexistence in agriculture
  - definition of 175
  - GMOs, impact of *see under* genetically modified organisms (GMOs)
- liability law 187–8
  - role of 176–7
  - Switzerland, new legislation in 183–7
- Monsanto v. Schmeiser* 178–82
- nuisance caused by use of GMOs 177–8
- coherence in international trade
  - regulation 228–37, 275–80
  - EC as example of 200–1
  - measures to improve 53–4, 200–1
- Committee on Economic, Social and Cultural Rights
  - human rights and IP, statement on 42–3
- commodity chemicals
  - definition of 152
- common heritage of humanity concept 324–8
- competition law, interaction with intellectual property 51–2
- competitiveness, role of patents in 9–10
- compulsory licensing 85–6, 100, 105–6
- conflicts between Agreements *see also* presumption against conflict
  - case law 220–1
  - lex posterior derogat legi priori*, avoidance of 222–7
  - lex specialis* doctrine 224–5
  - WTO and MEAs 271–5
  - WTO case law, in 220–1
- constraint, human dignity
  - considerations as 294–6, 322–4
- consumer opinion
  - like products, as indicator of 265–6
  - women in agriculture, impact on 61, 62–3
- Convention on Biological Diversity (CBD)
  - interaction of WTO Agreements and MEAs, as to 215
  - national law, incorporation into 178
  - precautionary principle, as to 255–6
  - traditional knowledge, protection of 113, 127, 132, 137
  - TRIPS, harmonisation with 114
- cooperation between international bodies *see* mutual supportiveness between international agreements
- copyright, interaction of moral rights and human rights 27–8
- corn, usage in ethanol production 156–7, 160–1
- cross-border gambling, regulation of
  - human dignity considerations as basis for 298–300
- D**
- deference principle 275–80
  - lex specialis* doctrine as to 278–9
- definitions of biotechnology 3–4, 151–2
- developing countries
  - bilateral agreements on IP with EC/USA 115
- biofuels
  - production of 158
  - costs and competitiveness 161
  - R&D 162–4

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

346

INDEX

- developing countries (cont.)
    - differential treatment under WTO Agreements 8–9
    - IP protection, UK recommendations on 116
    - opportunities for developing domestic biotechnology businesses 12
    - patentability of 12
    - patents
      - benefitting from 10
      - policy on patentability 9
      - safety of GM products, regulating for 8
  - disclosure of geographical origin of biological resources
    - Biotechnology Directive as to 98–100
    - TRIPS as to 84–5
  - discrimination
    - gender issues *see* gender issues
    - trade regulation, in 191–2
  - dispute settlement, improving
    - international co-operation in 54
  - DNA *see* genes and gene sequences
  - Doha meeting of WTO
    - harmonisation of CBD and TRIPS, as to 114
    - interaction of WTO Agreements and MEAs, as to 212–14
    - mutual supportiveness, on measures to promote 230
  - domestic law *see* national law
  - drugs
    - patents and human rights issues 41
    - women's access to HIV/AIDS treatments 66
  - E
  - economic sustainability 9–11
  - electricity *see* energy sector
  - embryonic stem cell research
    - ethical considerations 321–2
    - IBC/IGBC position on 321
    - legal status of embryos 322
  - embryos *see* human embryos
  - empowerment, human dignity
    - considerations as 293–4
  - energy sector *see also* biofuels
    - carbon dioxide emissions 154
      - biofuel's potential for reducing 155–6
      - reducing, methods of 154
    - demand for energy, future 152–3
    - electricity, worldwide access to 165
    - fossil fuels
      - future demand for 152–3
      - reserves of 152, 153
    - oil supply and demand 152–4
  - environment *see also* multilateral environmental agreements (MEAs)
    - agricultural policy to protect 189–90
    - biofuels, impact of 165–6
    - Cartagena Protocol as
      - environmental measure 209–10
    - national law and WTO, interaction of 263–7
    - WTO Agreements, protection under 225–7
  - environmental risk assessment *see* risk assessment
  - environmental sustainability, influence of GM products on 5–9
  - equal rights *see* gender issues
  - ethanol *see* biofuels
  - ethical, moral and religious
    - considerations *see also* human dignity; human rights
  - Biotechnology Directive 94–6, 102–3, 107
  - embryonic stem cell research 321–2
  - future trade regulation, influence on 50–1
  - human dignity *see* human dignity
  - human embryos, legal status of 322
  - human rights, relating to 29
  - medical research 13–14
  - patents measures in TRIPS as to 81, 107
- European Community (EC)
    - bilateral agreements on IP with developing countries 115
    - biofuels, production of 158
    - Biotechnology Directive *see* Biotechnology Directive (EC)

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

- coherence between international and national levels, as example of 200–1
- commercialisation of the human genome, as to 326–7
- consumer opposition to GM foods, impact on women farmers in developing countries 61, 62–3
- GM products, regulatory approach to 6–7
  - Biotech case as to 168, 171–3
  - member states' approaches to patenting 100–6
  - substantial equivalence, approach to 250, 251–2
- European Patent 86–8
- F**
- farming *see* agriculture; coexistence in agriculture
- first-generation biofuels 159
- flex-fuel vehicles 156
- food aid *see under* food security
- Food and Agriculture Organization (FAO), role in development of safety standards 236–7, 248–9
- food production *see also* food security
  - impact of biotechnology on 60–1
- food security
  - definition of 193
  - food aid, effect of GM products on 8
  - impact of biotechnology on 61, 195–6
  - international law, in 193–5
  - liberalisation of trade policy, impact of 63–4
  - potential for improving 13
- fossil fuels *see under* energy sector
- fuel cells 154–5
- Future of the WTO, The* (Sutherland Report) 230–1
- G**
- gambling *see* cross-border gambling, regulation of
- gender issues 56–74 *see also* women
  - anti-discrimination and equal rights 56–7
  - gender mainstreaming 57, 66–73
  - sustainable development, in relation to 57–8
- General Agreement on Tariffs and Trade (GATT)
  - human rights, interaction with 35–7
  - national regulation of trade in GMOs, interaction with 233–4, 238–40
  - national treatment principle 170
- General Agreement on Trade in Services (GATS), interaction with human rights 37–8
- genes and gene sequences
  - patentability of
    - animal and plant 91
    - human 91–4, 101–2, 106–7
- genetic engineering *see* biotechnology; human cloning; human genetic engineering
- genetic enhancement, human *see* human cloning
- genetic resources *see* biological resources
- genetically modified (GM) products *see also* genetically modified organisms (GMOs)
  - environmental sustainability, influence on 5–9
  - food aid, effect on 8
  - food security, effect on 61
  - GMOs *see* genetically modified organisms (GMOs)
  - labelling of, role in future trade regulation 50
  - patenting, human rights issues on 39–40
  - safety regimes 8
  - substantial equivalence with non-GM products 250–2
  - traditional societies, effect on 11–12
  - women in agriculture, impact on 60–1
  - WTO, regulatory role of 19–20
- genetically modified organisms (GMOs) *see also* LMOs *under* Cartagena Protocol on Biosafety (Cartagena protocol)
  - Biotechnology Directive as to 89–91

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

348

INDEX

- genetically modified (cont.)
  - coexistence in agriculture, impact
    - on 175–7, 182–3
  - coexistence of farming methods,
    - impact on
      - nuisance caused by use of
        - GMOs 177–8
    - Monsanto v. Schmeiser* case 178–82
  - control of
    - national and international trade
      - law, interaction of 190–2
      - GATT 233–4, 238–40
      - SPS Agreement 232–6, 240–2
      - Switzerland, new legislation in
        - 183–7
    - liability law as to 187–8
    - licensing law, Swiss 185–7
    - living characteristics of
      - risk assessment, as to 188–9
    - national treatment principle as
      - to 170
    - patentability of 78–81
    - plants *see* plants
    - precautionary principle as to 232–6,
      - 240–2
    - safety standards, development of
      - 231–7
    - trade policy considerations 14
  - GMOs *see* genetically modified organisms (GMOs)

H

  - health and healthcare *see also* human
    - cloning; human genetic
      - engineering
    - compulsory licensing of drugs 100,
      - 105–6
    - precautionary principle, application
      - of 258
    - TRIPS, protection in 85–6, 108
    - women 66
    - WTO Agreements, protection
      - under 225–7
  - hierarchy of agreements
    - absence of 227
    - no hierarchy principle 275–80
  - HIV/AIDS treatments
    - women's access to 66
  - human body and genetic material,
    - patentability of 81, 91–4,
      - 101–2, 106–7
  - human cloning
    - human dignity considerations
      - 307–8
    - reproductive cloning
      - prohibition of 288–9, 320–1
      - local morality, basis in
        - 289–90
    - therapeutic cloning, human dignity
      - considerations 309–11
  - human dignity 309–11
    - concepts of 292–3
      - basis for trade restrictions, as
        - 298–300, 312–14
      - constraint, as 294–6, 322–4
      - differing influences on trade
        - regulation 308–12
      - empowerment, as 293–4
      - tension between concepts 296–8
    - human rights, as basis of 304–8
  - human embryos
    - human rights, entitlement to
      - 309–11
    - legal status of 322
  - human genetic engineering *see also*
    - UNESCO Declarations on
      - human genetic engineering
    - cloning *see* human cloning
    - common heritage of humanity
      - concept as constraint 324–8
    - embryonic stem cell research *see*
      - embryonic stem cell research
    - feasibility of international
      - agreement on 341–2
    - humanity, concept of 324
    - patentability of gene sequences
      - 91–4, 101–2, 106–7
    - UNESCO Declarations
      - development of 318–20
      - patentability, as to 334–41
      - research, as to 328–34
  - human genome
    - common heritage of humanity,
      - whether part of 324–8
    - EC policy on commercialisation of
      - 326–7

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

- Human Genome Declaration *see*  
 UNESCO Declarations on  
 human genetic engineering
- human rights 17–25 *see also* gender  
 issues; human dignity  
 anti-discrimination 56–7  
 application of 29–32  
 ban on biotechnological weapons,  
 support for 29  
 Biotechnology Directive as to 96–8,  
 103, 107  
 common heritage of humanity  
 concept 324–8  
 competition aspects of future trade  
 regulation, interaction with  
 51–2  
 development of, factors influencing  
 300–1  
 applicability of rights 303–4  
 conflicting rights 302  
 consent, granting or withholding  
 of 302  
 curtailment of rights 303  
 entitlement to rights 304  
 extent of responsibilities 302  
 recognition of rights and their  
 scope 301  
 drugs, patenting of 41  
 embryos, of 309–11, 322  
 equal rights 56–7  
 ethical, moral and religious  
 considerations 29  
 future trade regulation, influence  
 on 50–1  
 future trade regulation, influence on  
 47–54  
 GATS, as to 288  
 GATS, interaction with 37–8  
 GATT as to 288  
 GATT, interaction with 35–7  
 human dignity, basis in 304–8  
 human genetic research, as to 328–34  
 humanity, concept of 324  
 intellectual property, interaction  
 with 27–9, 38–47  
 Committee on Economic, Social  
 and Cultural Rights,  
 statement by 42–3
- interpretation of trade law, influence  
 on 32–4  
 labelling of products, influence on 50  
 moral rights in copyright,  
 interaction with 27–8  
 necessary factor in trade regulation,  
 as 26–9, 287–8  
 patenting of drugs 41  
 precautionary principle, influence  
 on 49–50  
 purpose of 23  
 risk assessment, influence on 48–9  
 burden of proof 49  
 risk management, influence on 49  
 SPS Agreement, interaction with 35  
 principle of consistency 50  
 TBT Agreement, interaction with  
 35–6  
 TIP-rights, interaction with 28  
 TRIPS as to 38–47, 82, 107  
 usage of technology, issues of 31  
 WTO law, in 35  
 procedural standards 53
- humanity, concept of 324
- I**
- indigenous knowledge *see* traditional  
 knowledge
- innovation  
 effect of regulation on 10–11
- intellectual property (IP) *see also*  
 patents; traditional  
 knowledge
- Africa, in 111–12  
 model law 112–15  
 anti-trust rules, need for 201–2
- bilateral agreements between EC/  
 USA and developing  
 countries 115
- Biotechnology Directive *see*  
 Biotechnology Directive (EC)
- competition law in future trade  
 regulation, interaction with  
 51–2
- developing countries, in  
 UK recommendations on 116
- future trade regulation, influence on  
 47–54

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

350

INDEX

- intellectual property (IP) (cont.)
  - human rights, interaction with 27–9
  - TRIPS 38–47
  - sharing scientific data, UNESCO declarations on 331–4
  - sustainable development, issues of 45–7
  - TIP-rights *see* traditional intellectual property rights (TIP-rights)
  - traditional knowledge, protection of *see* traditional knowledge
  - TRIPS *see* Agreement on Trade-Related Investment Measures (TRIPS)
  - UPOV *see* International Convention for the Protection of New Varieties of Plants (UPOV)
  - WIPO *see* World Intellectual Property Organization (WIPO)
- Intergovernmental Bioethics Committee (IGBC) as to embryonic stem cell research 321
- International Bioethics Committee (IBC) as to embryonic stem cell research 321
- International Convention for the Protection of New Varieties of Plants (UPOV) 111
  - Africa, adoption in 115
  - African Model Legislation, as to 114
- International Covenant on Economic, Social and Cultural Rights (ICESCR) as to food security 193–5
- International Declaration on Human Genetic Data *see* UNESCO Declarations on human genetic engineering
- international trade regulation 50 *see also* World Trade Organisation (WTO)
  - Cartagena Protocol *see* Cartagena Protocol on Biosafety (Cartagena protocol)
  - Codex Alimentarius* standards, use of 232–6, 240–2
  - coherence *see* coherence in international trade regulation
  - food security, as to 193–5
  - future regulation
    - anti-trust rules, influence of 52
    - elements of 47–54
  - gender issues *see* gender issues; women
  - human rights, interaction with *see* human rights
  - interaction with human rights *see* human rights
  - interaction with national law 16, 17, 22
  - interaction with other areas of law 15
  - issues faced by, summary of 20–2
  - labelling of products, role of 50
  - liberalisation of, impact on agriculture 63–4
  - MEAs *see* multilateral environmental agreements (MEAs)
  - national law, interaction with 190–2, 205–7
  - overview of 14–16, 25–6
  - precautionary principle, role of 49–50
  - precautionary principle, status of 258–60
  - risk assessment, role of 48–9
    - burden of proof, allocation of 49
  - risk management, role of 49
  - role of 15–16, 17–18, 22–3
  - social sustainability, influence on 13
  - sources of 15, 16
  - standardisation to promote mutual supportiveness 231–7
  - traditional knowledge, protection of *see* traditional knowledge
- International trade regulation Commission, development of *lex specialis* doctrine 224–5
- International Treaty on Plant Genetic Resources for Food and Agriculture
  - WTO Agreements, interaction with 216
  - absence of hierarchy 227



Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

## INDEX

351

## K

Kyoto Protocol 164

## L

labelling of products, role in future  
trade regulation 50*lex posterior derogat legi priori*,  
avoidance of 222–7*lex specialis* doctrine 224–5

deference principle, as to 278–9

liability law

coexistence in agriculture *see under*  
coexistence in agriculture

future trade regulation, influence on 52

GM products 7

licensing

compulsory 85–6, 100, 105–6

Swiss law, under 185–7

like products 170

consumer opinion as indicator of  
265–6

WTO as to 263–4

exceptions to rules 266–7

PPM-based criteria, role of 265–6

living characteristics of GMOs, risk  
assessment of 188–9living modified organisms (LMOs) *see**under* Cartagena Protocol on  
Biosafety (Cartagena protocol)

## M

medical research

ethical considerations 13–14

human rights issues of drug patents 41

microorganisms

patentability of

Biotechnology Directive, under  
89, 101*Monsanto v. Schmeiser* 178–82

multilateral environmental agreements

(MEAs) 235, 240–37, 242–4

Cartagena Protocol *see* CartagenaProtocol on Biosafety  
(Cartagena protocol)

development of 267–9

WTO Agreements, interaction with

171, 212–17, 235–6,

244–5, 270–1

absence of hierarchy 227

CBD as to 215

comparison of WTO and MEAs  
267–9

conflicts 271–5

*lex posterior derogat legi priori*,  
avoidance of 222–7*lex specialis* doctrine 224–5mutual supportiveness principle  
228–37

no hierarchy, mutual

supportiveness and

deference principle 275–80

presumption against conflict  
217–21mutual supportiveness *see* coherence  
in international trade  
regulation

## N

national trade regulation

CBD into, incorporation of 178

human dignity considerations as  
basis for 298–300, 312–14convergence and divergence  
between approaches  
308–12international obligations, need to  
balance 11traditional knowledge, protection of  
proposals for strengthening 136WTO Agreements, interaction with  
16, 17, 22, 190–2, 205–7

environmental legislation 263–7

GATT 233–4, 238–40

trade in GMOs 232–3, 237–8

national treatment principle

(GATT) 170

no hierarchy principle 275–80

non-discrimination in WTO law 26

nuisance, law of

GMOs in farming, use of 177–8

*Monsanto v. Schmeiser* case  
178–82

nutrition, improvements in 60–1

## O

oil *see under* energy sector

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

352

INDEX

## P

## patents

- animals 89–91, 101, 106
- benefits from, sharing 10
- Biotechnology Directive *see*
  - Biotechnology Directive (EC)
- competition law, interaction with 51–2
- competitiveness, role in encouraging 9–10
- compulsory licensing 85–6, 100, 105–6
- developing countries' policy on patentability 9
- EC member states' approaches 100–6
- economic sustainability, role in 9–10
- environmental sustainability, role in 7–8
- ethical, moral and religious considerations 81, 94–6, 102–3, 107
- European Patent 86–8
- genes and gene sequences 91, 101–2
- GMOs 78–81, 89–91
- governmental approaches to use of 9
- human body and genetic material, as to 81, 91–4, 101–2, 106–7
- human genetic engineering, UNESCO declarations as to 334–41
- human health issues 85–6, 108
  - compulsory licensing of drugs 100
- human rights 39–40, 82, 96–8, 103, 107
- international competitiveness, influence on 9–10
- medical research 14
- microorganisms 89, 101
- plants 89–91, 101, 106
- recombinant proteins 88–9
- risk assessment, role in 7–8
- stem cells 93–4, 101–2
- traditional knowledge
  - impact on 118, 121–3
  - protection of 82–5, 98–100, 103–4, 107–8
  - suitability for 137–9
- TRIPS *see* Agreement on Trade-Related Investment Measures (TRIPS)

- WTO, protection by 10
- pharmaceuticals *see* drugs
- plants
  - Africa
    - breeding in 111–12
    - model law protection for 112–15
    - usage of plant biotechnology in 109–10
  - biofuels, as sources of 155
  - patentability of
    - Biotechnology Directive as to 89–91, 101, 106
    - genes and gene sequences 91
    - TRIPS as to 78–81, 106
  - taxonomy of 89–90
- potato varieties
  - taxonomy of 89–90
- precautionary principle
  - Cartagena Protocol 167, 234–5, 240, 255–6
  - case law 232–6, 240–2
  - content of 254–8
  - future trade regulation, role in 49–50
  - health, application to 258
  - origins of 252–4
  - risk assessment as to 257
  - risk management, role in 257
  - status in international law 258–60
  - uncertainty, in presence of 256–7
  - WTO approach to 280–4
    - SPS Agreement 232–6, 240–2, 281
- presumption against conflict, between WTO and MEAs 217–21
- principle of consistency, role in future trade regulation 50
- process and production methods (PPMs) as basis for determining like products 265–6
- protectionism, WTO's role in preventing 11

## R

- recombinant proteins, Biotechnology Directive as to 88–9
- regulatory regimes
  - harmonisation of 15
  - innovation, effect on 10–11

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

## INDEX

353

- reproductive human cloning *see under* human cloning
- research and development
  - human genetic engineering, UNESCO declarations as to 328–34
  - medical research, ethical considerations 13–14
- research and development (R&D)
  - biofuels 162–4
- Rio Declaration, as to precautionary principle 254–8
- risk assessment
  - biofuels, trade in 165–6
  - Cartagena Protocol as to 209, 233–4, 238–40
  - future trade regulation, role in 48–9
  - living characteristics of GMOs, as to 188–9
  - patent procedures, role of 7–8
  - precautionary principle, as to 257
  - risk–benefit analysis 236–7, 248–9
  - risk management, role in 237, 249–50
  - SPS Agreement as to 168–9
  - standards for, development of 235, 240–37, 242–4
  - Swiss law, under 184
- risk–benefit analysis 236–7, 248–9
- risk management
  - definition of risk 236, 247–8
  - future trade regulation, role in 49
  - precautionary principle, as to 257
  - substantial equivalence 250–2
  - uncertainty in 237, 249–50
- Rotterdam Convention on the Prior Informed Consent Procedure for Hazardous Chemicals and Pesticides in International Trade
  - interaction of WTO Agreements and MEAs, as to 215
  - absence of hierarchy 227
- S**
- scientific uncertainty *see* uncertainty in risk management
- second-generation biofuels 159
- social sustainability 11–14
- soft law on human biotechnology *see* UNESCO Declarations on human genetic engineering
- speciality chemicals, definition of 152
- SPS Agreement *see* Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement)
- standards
  - basis for trade regulation, as 232–3, 234–5, 237–8, 240
  - development of 231–7
  - FAO's role in developing safety standards 236–7, 248–9
- stem cells, patentability of 93–4, 101–2, 106–7
- Stockholm Convention on Persistent Organic Pollutants
  - precautionary principle, as to 255–6
  - WTO Agreements, interaction with 215
- substantial equivalence (GM/non-GM products) as to risk management 250–2
- sugar cane usage in ethanol production 156
- sui generis* systems
  - traditional knowledge, protection of 141–7
- sui generis* systems for protection of traditional knowledge 139–41
- sustainable development 5
  - economic *see* economic sustainability
  - environmental *see* environmental sustainability
  - gender issues in relation to 57–8
  - intellectual property, interaction with 45–7
  - social *see* social sustainability
- Sutherland Report (*Future of the WTO*) as to cooperation between WTO and MEAs 230–1
- Switzerland, liability law as to nuisance from GMOs in farming 175–92

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

354

INDEX

## T

taxonomy of plants 89–90

TBT Agreement *see* Agreement on  
Technical Barriers to Trade  
(TBT Agreement)

trade disputes, sources of 20–2

traditional intellectual property rights  
(TIP-rights), interaction  
with human rights 28

traditional knowledge

biological resources, relationship to  
120–1bioprospecting and biopiracy,  
impact of 121–2

CBD as to 113

nature of 118–23

patent law, impact of 118, 121–3

protection of 65, 107–8, 126–34

African Model Legislation 112–15  
Biotechnology Directive 98–100,  
103–4

CBD 132, 137

patents as suitable means of 137–9  
proposals for strengthening  
134–47

national law, in 136

*sui generis* systems for 139–47

TRIPS 82–5, 107–8, 132–4

WIPO 131–2

World Bank, statement by 129–30

WTO 123–6, 132–4

women, role of 64–5

traditional societies *see also* traditional  
knowledge

effect of GM products on 11–12

gender issues *see* gender issues;  
womentreaties *see also* entries for specific treaties;  
*see also under* United Nationscommon heritage of humanity, as  
to 325

deference by WTO to 278–9

human dignity, as to 293–5

interaction of WTO Agreements and  
MEAs, as to 214–17*lex posterior derogat legi priori*,  
avoidance of 222–4*lex specialis* doctrine 224–5origins of precautionary principle in  
252–4TRIPS *see* Agreement on Trade-  
Related Investment  
Measures (TRIPS)

## U

uncertainty in risk management 237,  
249–50

precautionary principle, as to 256–7

UNESCO Declarations on human  
genetic engineeringcommon heritage of humanity  
concept 324–8

human dignity, as to 323–4

human genetic research, as to 328–34

patentability, on 334–41

TRIPS, interaction with 334–41

WTO Agreements, interaction with  
333–4

United Kingdom (UK),

recommendations on IP  
protection in developing  
countries 116United Nations (UN) *see also* entries  
for individual UN bodies

Convention to Combat

Desertification

interaction of WTO Agreements  
and MEAs, as to 215gender mainstreaming, measures  
supporting 71–3

mutual supportiveness, on 229

no hierarchy, mutual supportiveness  
and deference principle,  
support for 279–80safety standards, role in developing  
standards for 235–6, 244–5traditional knowledge, protection of  
127–9

United Nations Environment

Programme (UNEP), role in  
developing safety standards  
237, 249–50Universal Declaration on Bioethics and  
Human Rights *see* UNESCO  
Declarations on human  
genetic engineering

Cambridge University Press

978-0-521-88360-3 - Genetic Engineering and the World Trade System: World Trade Forum

Edited by Daniel Wuger and Thomas Cottier

Index

[More information](#)

## INDEX

355

- Universal Declaration on the Human Genome and Human Rights  
  *see* UNESCO Declarations on human genetic engineering
- UPOV *see* International Convention for the Protection of New Varieties of Plants (UPOV)
- USA
  - bilateral agreements on IP with developing countries 115
  - cross-border gambling, regulation of 298–300
  - ethanol production 156–7
  - tax credit system 157
  - GM products, regulatory approach to 6
  - substantial equivalence, approach to 250, 251–2
- usage of technology, human rights issues 31
- uses of biotechnology, overview of 18
- W
  - weapons, human rights support for restrictions on 29
- WIPO *see* World Intellectual Property Organization (WIPO)
- women 12 *see also* gender issues
  - agriculture, and
  - barriers to use of biotechnology
  - lack of access 61–2
  - lack of take-up 62
  - opposition from EC consumers 61, 62–3
  - liberalisation of trade policy 63–4
  - long-term health concerns 61, 62–3
  - role of women 59–60, 64
  - HIV/AIDS treatments, access to 66
  - traditional knowledge, role in 64–5
- World Bank, statement on protection of traditional knowledge 129–30
- World Health Organization (WHO),
  - role in developing safety standards 236, 247–8
- World Intellectual Property Organization (WIPO)
  - African Model Legislation, as to 114
  - traditional knowledge, protection of 126–32
- World Trade Organization (WTO)
  - 114, 260–3 *see also* international trade regulation
  - biofuels, regulation of
  - Cartagena Protocol 166–7
  - GATT 170
  - SPS Agreement 167–9
  - TBT Agreement 169–70
  - Biotech* case as to interpretation of Agreements 171–3
  - Cartagena Protocol, interaction with *see under* Cartagena Protocol on Biosafety (Cartagena protocol)
  - dispute settlement 235, 240–37, 242–4
  - case law as to conflicts between Agreements 220–1
  - cross-border gambling regulation case 298–300
  - current state of biotechnology regulation 25–6
  - developing countries, differential treatment for 8–9
  - development of 267–9
  - Doha meeting *see* Doha meeting environment, protection for 225–7
  - GATS *see* General Agreement on Trade in Services (GATS)
  - GATT *see* General Agreement on Tariffs and Trade (GATT)
  - health and healthcare, protection for 225–7
  - human rights
    - explicit reference to 26–9
    - WTO procedures, role in 53
  - interpretation of Agreements, *Biotech* case as to 171–3
  - like products, as to *see under* like products
  - exceptions to rules 266–7
  - PPM-based criteria, role of 265–6
  - MEAs, interaction with *see under* multilateral environmental agreements (MEAs)

- World Trade Organization (cont.)
  - national law, interaction with *see* national trade regulation
  - non-discrimination, reference to 26
  - precautionary principle, approach to 232–6, 240–2, 280–4
  - role of 260–3
    - patents, protection of 10
    - protectionism, prevention of 11
    - trade in GMOs, regulation of 19–20
- Sutherland Report on future of WTO, as to cooperation with MEAs 230–1
- traditional knowledge, protection of 123–6, 132–4
- TRIPS *see* Agreement on Trade-Related Investment Measures (TRIPS)
- UNESCO declarations, interaction with 333–4